Exabis Library
Welcome to the e-CCO Library!
P440 Polimedication in patients with inflammatory bowel disease: prevalence and outcomes in a retrospective unicentric series
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P440: Comparison of infliximab serum levels between venous and capillary blood in paediatric IBD patients using novel blood sampling technology
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P440: Early changes in the pharmacokinetic profile of vedolizumab-treated patients with inflammatory bowel disease may predict response after dose optimisation
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P440: First results of the BELCOMID study: BELgian Cohort study of COVID-19 in Immune Mediated Inflammatory Diseases (IMID)
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P440: Loss of response and dose escalation of infliximab and adalimumab in Ulcerative Colitis patients: A Systematic Review and Meta-analysis.
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P440: Prevalence of NUDT15 polymorphisms and incidence of thiopurine-induced leukopenia in Inflammatory Bowel Disease patients: A systematic review and meta-analysis
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P440: Staged surgical management of complicated ileo-colonic Crohn’s Disease
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P440: Therapeutic drug monitoring of infliximab for the management of loss of response in inflammatory bowel disease: an observational multicenter study
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P441 Efficacy of biosimilar infliximab CT-P13 among inpatients with severe steroid-refractory colitis
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P441: Adalimumab versus ustekinumab as first-line biological in a real-life cohort of moderate-to-severe Crohn's disease.
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P441: Clinical efficacy, drug sustainability and results from therapeutic drug monitoring in Crohn’s disease patients treated with ustekinumab – 1-year follow-up of a prospective, nationwide, multicenter cohort from Hungary
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P441: Conjoint analysis for quantification of inflammatory bowel disease patients’ preferences for outcome metrics
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P441: Higher education, professional occupation and upper socio-economic status is associated with lower adherence to medications in patients with inflammatory bowel disease
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P441: Long-term CD treatment failure and dose modification rates with vedolizumab and other biologics: Results from a large prospective observational study
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P441: Long-term immunogenicity of vedolizumab in ulcerative colitis and Crohn’s disease (GEMINI Programme)
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P441: Thalidomide induces clinical remission and mucosal healing in adults with active Crohn's disease: a prospective open-label study
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P442 Long-term quality of life after surgery for perianal Crohn’s disease
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P442: Endoscopic resection of visible precancerous lesions in patients with colonic Inflammatory Bowel Disease
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P442: Evaluation of safety and efficacy of laparoscopic surgery for ulcerative colitis
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P442: Incidence of pneumonia and other respiratory tract infections with vedolizumab treatment for inflammatory bowel disease: clinical trial experience
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM